Drugs / Equine rabies immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04478084 | Aug 2020 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Equine rabies immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04478084 ↗ |
| Known as | ERIG | “ERIG” NCT04478084 ↗ |
| Modality | Protein / enzyme biologic | “Equine rabies immunoglobulins (ERIG)” NCT04478084 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular” NCT04478084 ↗ |